Zhitong Financial App News, Borui Pharmaceutical (688166.SH) announced that Borui Pharmaceutical (Suzhou) Co., Ltd. (“Borui Pharmaceutical”), a wholly-owned subsidiary of the company, recently received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration, agreeing to conduct clinical trials of Borui Pharmaceuticals BGM0504 tablets in adult type 2 diabetics.

BGM0504 is a GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulin-promoting polypeptide) receptor dual agonist independently developed by the company. It can effectively activate the downstream pathways of both receptors, produce biological effects such as blood sugar control, weight loss, and treatment of fatty liver disease (MASLD) associated with metabolic dysfunction, showing potential for treating various metabolic diseases. BGM0504 tablets are an oral dosage form of BGM0504. Phase I clinical studies of its overweight/obesity indications have been completed in China and the US. Currently, phase II clinical studies are being carried out in China, and all participants have been enrolled. As of the date of disclosure of the announcement, no similar targeted oral dosage forms have been approved for marketing in the world.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.